Massachusetts General Hospital is the original and largest teaching hospital of Harvard Medical School, Harvard University located in the West End neighborhood of Boston, Massachusetts. Massachusetts General Hospital houses the world's largest hospital-based research program, the Mass General Research Institute, with an annual research budget of more than $1.2 billion in 2021. It is the third-oldest general hospital in the United States with a patient capacity of 999 beds. Along with Brigham and Women's Hospital, Mass General is a founding member of Mass General Brigham, formerly known as Partners HealthCare, the largest healthcare provider in Massachusetts.
Brigham and Women's Hospital (BWH) is the second largest teaching hospital of Harvard Medical School and the largest hospital in the Longwood Medical Area in Boston, Massachusetts. Along with Massachusetts General Hospital, it is one of the two founding members of Mass General Brigham, the largest healthcare provider in Massachusetts. Robert Higgins, MD, MSHA serves as the hospital's current president.
Frederick Pei Li was a Chinese-American physician. He is most famous for his discovery, together with his colleague Joseph Fraumeni, of Li–Fraumeni syndrome, which is caused by germline mutations of the p53 tumor suppressor gene and genetically predisposes families to high rates of cancer.
Sidney Farber was an American pediatric pathologist. He is regarded as the father of modern chemotherapy for his work using folic acid antagonists to combat leukemia, which led to the development of other chemotherapeutic agents against other malignancies. Farber was also active in cancer research advocacy and fundraising, most notably through his establishment of the Jimmy Fund, a foundation dedicated to pediatric research in childhood cancers. The Dana–Farber Cancer Institute is named after him.
The Israel Cancer Research Fund (ICRF) is a fund for cancer research. The ICRF was founded in 1975 by a group of American and Canadian physicians, scientists, and laypeople who sought to prevent the permanent loss of Israel's cancer researchers to foreign universities due to the lack of funding in Israel for newly minted Ph. D.s, post-doctoral fellows and accomplished young scientists (a phenomenon known to many as Israel's "brain drain"). With chapters in New York, Los Angeles, Chicago, Toronto, Montreal, and Jerusalem, ICRF annually sponsors a grant review process conducted by an expert panel of U.S. and Canadian scientists and oncologists and modeled on the NIH grant-making process.
George Quentin Daley is the Dean of the Faculty of Medicine, Caroline Shields Walker Professor of Medicine, and Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. He was formerly the Robert A. Stranahan Professor of Pediatrics at Harvard Medical School, Director of the Stem Cell Transplantation Program at Boston Children's Hospital, and an investigator of the Howard Hughes Medical Institute, Associate Director of Children's Stem Cell Program, a member of the Executive Committee of the Harvard Stem Cell Institute. He is a past president of the International Society for Stem Cell Research (2007–2008).
Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.
The Szent-Györgyi Prize for Progress in Cancer Research, established by National Foundation for Cancer Research (NFCR) and named in honor of Albert Szent-Györgyi, Nobel laureate and co-founder of NFCR, has been awarded annually since 2006 to outstanding researchers whose scientific achievements have expanded the understanding of cancer and whose vision has moved cancer research in new directions. The Szent-Györgyi Prize honors researchers whose discoveries have made possible new approaches to preventing, diagnosing and/or treating cancer. The Prize recipient is honored at a formal dinner and award ceremony and receives a $25,000 cash prize. In addition, the recipient leads the next "Szent-Györgyi Prize Committee" as honorary chairman.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Edward J. Benz Jr. is the former president of Dana–Farber Cancer Institute in Boston, Massachusetts., and the Richard and Susan Smith Professor of Medicine as well as a professor of genetics at Harvard Medical School.
Carolyn Kaelin was an American cancer surgeon. She worked at the Dana–Farber Cancer Institute and founded the Comprehensive Breast Health Center at Brigham and Women’s Hospital in 1995.
Nathanael S. Gray is an American chemist. He serves as Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana–Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego. C4 Therapeutics, which offered IPO in 2020, was founded based on the ground-breaking research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gray, while he was professor at Harvard Medical School. Before moving to Stanford University, Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm. In 2020, Gray Lab permanently moved to Stanford University, that was stated by Stuart Schreiber, co-founder of Broad Institute as "Stanford's huge gain".
Mary-Ellen Taplin, is a research oncologist at Dana Farber Cancer Institute and Brigham and Women's Hospital in Harvard's Longwood Medical and Academic Area.
Jay Steven Loeffler was an American physician at Massachusetts General Hospital where he served as Chair of the Department of Radiation Oncology since 2000. He was the Herman and Joan Suit Professor of Radiation Oncology and Professor of Neurosurgery at Harvard Medical School.
Matthew Kulke is an American cancer researcher. He is the Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and "Zoltan Kohn Professor" at the Boston University School of Medicine. His work has shed light on the molecular characteristics of neuroendocrine tumors and has led to the development of multiple new treatments for this condition. His research studies led to the development and approval of telotristat ethyl, a tryptophan hydroxylase inhibitor, for the treatment of patients with carcinoid syndrome. He has also contributed to early and late stage clinical trials of temozolomide, sunitinib, everolimus, and peptide receptor radiotherapy for neuroendocrine tumors.
Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).
Scott Allen Armstrong is an American pediatric oncologist and cancer biologist focused on chromatin-based control of gene expression in cancer and therapeutic discovery. Armstrong and his team were the first to isolate rare leukemia stem cells in a mouse model of leukemia.
Daphne Adele Haas-Kogan is an American radiation oncologist. She is the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School.
Nancy Lin is an American oncologist who works at the Dana-Farber Cancer Institute and is an Associate Professor of Medicine at Harvard Medical School. Her research considers new diagnostic strategies and treatment pathways for HER2 positive breast cancer.
James D. Griffin is an American physician-scientist. He is currently Professor of Medicine at Harvard Medical School, Chair of Medical Oncology at Dana–Farber Cancer Institute, and Director of Medical Oncology at Brigham and Women's Hospital. He is considered an expert in medical oncology and is widely recognized for his research in the clinical and biologic aspects of hemotologic malignancies.
